


## Supplemental Information



**Figure S1.** Disposition of participants in a secondary analysis of effects of intravenous ketamine on suicidal ideation in treatment-resistant depression.

<sup>a</sup>Lack of suicidal ideation defined as Montgomery-Åsberg Depression Rating Scale suicide item (MADRS-SI) score < 2.

<sup>b</sup>One study participant received treatment with ketamine prior to enrollment in the clinical trial. To maintain study blind, this individual received a single ketamine infusion during Phase 1 but did not receive the crossover midazolam infusion (considered a protocol deviation). This participant was excluded from this secondary analysis.